OPKO Health (NASDAQ: OPK) reported Q4 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $275.5 million versus the consensus estimate of $310.82 million.

• Consolidated revenues for the three months ended December 31, 2016 of $275.5 million were consistent with the comparable period of 2015 revenue of $276.2 million. The 2016 period benefited from increased revenue from services at BioReference of $12.8 million, which was offset by a non-recurring $15.0 million milestone payment that was received during the comparable period of 2015 related to Varubi™.
• Net loss for the three months ended December 31, 2016 was $13.7 million compared with net income of $1.6 million for the 2015 period. The three months ended December 31, 2016 included the launch related activities for RAYALDEE, including the 50 person commercial organization. Net (loss) income during the three month periods include significant non-recurring and non-cash activities:- During the three months ended December 31, 2015, revenue included a $15.0 million milestone payment related to the first commercial sale of Varubi™ by TESARO.- Other income and (expense) was $7.7 million and ($15.9) million in the 2016 and 2015 periods, respectively, primarily related to the change in fair value of derivative instruments. The change in fair value is principally related to an embedded derivative in OPKO’s January 2013 convertible senior notes due in 2033. The 2015 period also included a ($7.3) million temporary impairment charge of an available for sale investment.
• Cash, cash equivalents and marketable securities were $168.7 million as of December 31, 2016.

For earnings history and earnings-related data on OPKO Health (OPK) click here.